Alliance Global Partners Initiates Coverage On NeuroSense Therapeutics With Buy Rating, Announces Price Target of $7.5
Alliance Global Partners Initiates Coverage On NeuroSense Therapeutics With Buy Rating, Announces Price Target of $7.5
Alliance Global Partners以買入評級開始對NeuroSense Therapeutics進行報道，宣佈目標
Alliance Global Partners analyst James Molloy initiates coverage on NeuroSense Therapeutics (NASDAQ:NRSN) with a Buy rating and announces Price Target of $7.5.
Alliance Global Partners分析師詹姆斯·莫洛伊開始報道NeuroSense Therapeutics（納斯達克股票代碼：NRSN），評級爲買入，並宣佈目標股價爲7.5美元
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。